Diphtheria Toxoid (30IU) + Haemophilus Type B Conjugate Vaccine (10mcg) + Pertussis Toxoid (4IU) + Tetanus Toxoid (60IU) (Medical Monograph)

Overview

A quadrivalent, combined, adsorbed, acellular vaccine for active immunization against diphtheria, tetanus, pertussis (whooping cough), and invasive diseases caused by Haemophilus influenzae type b (Hib). It is a sterile suspension for intramuscular injection, containing purified toxoids and a conjugate antigen adsorbed onto an aluminum adjuvant to enhance immunogenicity. It is a critical component of the National Immunization Schedule in India for primary and booster vaccination in infants and children.

The vaccine induces active immunity by stimulating the production of specific antibodies and memory B and T cells against the antigens. Diphtheria and Tetanus Toxoids: Inactivated forms of the exotoxins (Corynebacterium diphtheriae and Clostridium tetani) that induce neutralizing antibodies. Pertussis Toxoid: Inactivated form of the pertussis toxin from Bordetella pertussis, a key virulence factor. Haemophilus influenzae type b Conjugate Vaccine: The Hib capsular polysaccharide (polyribosylribitol phosphate, PRP) is chemically conjugated to a carrier protein (often Tetanus Toxoid). This conjugation converts the T-cell-independent PRP antigen into a T-cell-dependent antigen, eliciting a stronger, more durable immune response with robust memory, especially in infants.